Latest news with #SUPREX™
Int'l Business Times
18-06-2025
- Business
- Int'l Business Times
Passion, Plants, and Phase III: Devonian Health Group Is on a Mission to Disrupt Inflammation Therapy
While the industry might be dominated by synthetic compounds, billion-dollar VC funds, and long, uncertain development timelines, Devonian Health Group Inc. is proving there is another way. As a publicly traded company, under the leadership of its founder and CEO, Dr. André P. Boulet, Devonian has quietly advanced multi-target drug candidates and a cutting-edge cosmeceutical line, backed not by institutional investors but by a network of Canadian family offices made up of dentists, physicians, engineers, and entrepreneurs. Boulet's journey to this unconventional success story reads like a masterclass in risk, reinvention, and scientific conviction. "I'm a venture capitalist in my heart," Boulet says. "But I'm also a scientist. When I saw the anti-inflammatory results of this botanical extract technology from a university agriculture project, I knew this had real potential. So, I followed my instinct and took the risk." With a PhD in physiology-endocrinology, postdoctoral training in biochemistry and biophysics, and experience leading cardiovascular clinical research programs, Boulet's transition from academia to venture capital was swift. After climbing the pharmaceutical ladder and managing funds in Montreal, he exited his partnership and launched what would become Devonian Health Group in 2015. At its core, Devonian is a clinical-stage pharmaceutical company focused on autoimmune and inflammatory conditions, with its lead drug candidate, Thykamine ™, poised to enter Phase III clinical trials for atopic dermatitis and soon pediatric eczema. "Traditional pharma was built on the 'silver bullet,' one target, one mechanism," Boulet explains. "But now science is evolving. We're moving toward therapies that modulate multiple pathways. That's exactly what Thykamine does without shutting down important immune functions like TNF-alpha. That's why our efficacy is high, but side effects are minimal." What sets Devonian apart isn't just its marquee drug but the platform behind it. The company's patented SUPREX™ technology allows for water-based extraction, purification, and stabilization of Active Botanical Ingredients (ABIs) from plants and algae. These complexes modulate inflammation at the genetic level across multiple diseases, offering a broad pipeline of possibilities. To date, Thykamine™ has demonstrated strong results in its Phase II trial. Both gastrointestinal (ulcerative colitis) and dermatological (eczema) models have shown significant symptom relief and safety comparable to placebo. Remarkably, all this has been achieved without traditional VC backing. Boulet credits this to his deep network of entrepreneurial allies and his belief in business-first partnerships. "We've raised funds to advance to Phase III, built an extraction and production facility, and kept the company debt-free," he says. While the pharmaceutical arm garners headlines, Devonian's cosmeceutical division is equally ambitious. Operating under the Purgenesis™ brand, the company has developed a premium line of anti-aging creams containing its patented botanical ingredient R-Spinasome®, a photosynthetic cell extract with dynamic antioxidant properties. What makes Purgenesis™ unusual in the beauty space is its clinical rigor. Devonian has conducted peer-reviewed, pharma-grade clinical trials on the entire product line, something virtually unheard of in the cosmeceutical industry. "We've scientifically proven a reduction in wrinkles," says Boulet. "Not just pretty pictures, but peer-reviewed, published data. We're the only ones doing cosmeceuticals the pharma way." With day, night, and eye creams already developed and a professional-grade serum in the pipeline, Devonian is currently seeking commercial partners to bring Purgenesis™ to a global market hungry for results-backed skincare. Perhaps the most unusual aspect of Devonian's success is how personal it all feels. There are no Silicon Valley investors or hedge fund suits behind the curtain, just a network of entrepreneurs who believe in the mission. "Working with family offices is stimulating," Boulet says. "You get input from pharmacists, dentists, and industrialists. We face challenges together, and we have fun doing it." The company's headquarters in Québec includes a full-scale extraction and production facility, providing complete traceability from seed to pill. This vertical integration helps with both cutting costs, yes, but also ensuring product consistency. For Boulet, the journey has been one of passion and perseverance. "In life, there's always a risk," he reflects. "But if you surround yourself with the right people and believe in what you're building, that risk becomes your fuel. That's what Devonian is about: science, instinct, and community." As the company readies for Phase III trials in both pharmaceuticals and final-stage commercialization of its skincare line, Devonian Health Group stands as a testament to the power of conviction and the potential of plants to reshape the future of medicine.
Yahoo
14-02-2025
- Health
- Yahoo
Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine™ for Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH)
QUEBEC CITY, February 13, 2025--(BUSINESS WIRE)--Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, announces the filing of a new provisional patent application directed to the use of Thykamine™ for treating metabolic dysfunction-associated steatotic liver disease (MASLD), such as MASH. Backed by in vivo data, the provisional patent application displays the potential effectiveness of thylakoid extracts in treating and slowing the progression of metabolic dysfunction-associated steatotic liver disease (MASLD), such as MASH. "The filing of this new provisional patent application is another pivotal component of our broad strategy of expanding our already list of patents. Importantly, this filing is timely as we look to demonstrate the potential broad application of our technology," said Dr. André P. Boulet, Chief Scientific Officer of the Company. About MASLD/MASH1,2 Metabolic dysfunction-associated steatotic liver disease (MASLD) (formerly metabolic (dysfunction) associated fatty liver disease (MAFLD) or nonalcoholic fatty liver disease (NAFLD)) is the most common form of chronic liver disease with a worldwide prevalence of 20-30%. It is represented by fat accumulation in the liver, a condition that is commonly associated with features of the metabolic syndrome (MetS), such as obesity, type 2 diabetes, dyslipidemia, and hypertension. MASLD progresses to metabolic dysfunction-associated steatohepatitis (MASH), the hallmarks of which are inflammation, hepatocellular ballooning, and subsequent worsening fibrosis. Left untreated, MASH can ultimately progress to cirrhosis of the liver and hepatocellular carcinoma, liver failure and death. About Thykamine™ Thykamine™, the first pharmaceutical product issued from Devonian's SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a large Phase II study in adult patients with mild-to-moderate Atopic Dermatitis. Both Thykamine™ and SUPREX™ platform are covered by patents issued in several North American, European and Asian countries. About Devonian Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian's focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare Inc., focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability 'from the seed to the pill'. Devonian is traded publicly on the TSX Venture Exchange (the "Exchange") (TSXV: GSD) and on OTCQB exchange (OTCQB: DVHGF). For more information, visit References Ekstedt M, Nasr P and Kechagias S. Natural History of NAFLD/NASH. Curr Hepatology Rep. 16:391-397, 2017. Pierantonelli I. and Svegliati-Baroni G. Nonalcoholic Fatty Liver Disease: basic Pathogerenic Mechanisms in the Progression from NAFLD to NASH. Transplantation, 103(1): p e1-e13, 2019 Cautionary Note Regarding Forward-Looking Statements All statements, other than statements of historical fact, contained in this press release including but, not limited to those relating to the economical impact of clinical study, the efficiency of the high anti-inflammatory potency proven and the position of the Thykamine™ as a possible first line treatment of choice for several autoimmune conditions in the early stages of the disease, the reduced need for aggressive treatments with biologics and other immune modulators, that are associated with serious side effects and long term negative consequences, the grant of the patent and, generally, the above "About Devonian" and "About Altius" paragraphs, which essentially describes the Corporation's outlook, constitute "forward-looking information" or "forward-looking statements" within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release. View source version on Contacts Devonian Health Group Inc. Mr. Luc GregoirePresident & CEODr. Andre P. Boulet, PhDChairman, Chief Scientific OfficerTelephone: 1 (450) 979-2916E-mail: investors@ Renmark Financial Communications Inc. Mr. Ben OzerkevichTelephone: (416) 644-2020 or (212) 812-7680E-mail: bozerkevich@ Sign in to access your portfolio
